Found 3 hits in this display Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
Integrin alpha-V/beta-3
(Homo sapiens (Human)) | BDBM50403867
(CHEMBL2115098)Show SMILES OC(=O)C[C@H](NC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)c1ccc2OCOc2c1 |r,t:17| Show InChI InChI=1S/C22H24N4O6S/c27-19(26-22-23-8-1-9-24-22)7-4-14-3-6-18(33-14)21(30)25-15(11-20(28)29)13-2-5-16-17(10-13)32-12-31-16/h2-3,5-6,10,15H,1,4,7-9,11-12H2,(H,25,30)(H,28,29)(H2,23,24,26,27)/t15-/m0/s1 | PDB
UniProtKB/SwissProt
antibodypedia antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| PubMed
| n/a | n/a | 9 | n/a | n/a | n/a | n/a | n/a | n/a |
Aventis Pharma Deutschland GmbH
Curated by ChEMBL
| Assay Description Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50% |
Bioorg Med Chem Lett 11: 2011-5 (2001)
BindingDB Entry DOI: 10.7270/Q2N87930 |
More data for this Ligand-Target Pair | |
Integrin alpha-V/beta-3
(Homo sapiens (Human)) | BDBM50403867
(CHEMBL2115098)Show SMILES OC(=O)C[C@H](NC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)c1ccc2OCOc2c1 |r,t:17| Show InChI InChI=1S/C22H24N4O6S/c27-19(26-22-23-8-1-9-24-22)7-4-14-3-6-18(33-14)21(30)25-15(11-20(28)29)13-2-5-16-17(10-13)32-12-31-16/h2-3,5-6,10,15H,1,4,7-9,11-12H2,(H,25,30)(H,28,29)(H2,23,24,26,27)/t15-/m0/s1 | PDB
UniProtKB/SwissProt
antibodypedia antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| PubMed
| n/a | n/a | 1.43E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Aventis Pharma Deutschland GmbH
Curated by ChEMBL
| Assay Description Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50% |
Bioorg Med Chem Lett 11: 2011-5 (2001)
BindingDB Entry DOI: 10.7270/Q2N87930 |
More data for this Ligand-Target Pair | |
Integrin alpha-IIb/beta-3
(Homo sapiens (Human)) | BDBM50403867
(CHEMBL2115098)Show SMILES OC(=O)C[C@H](NC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)c1ccc2OCOc2c1 |r,t:17| Show InChI InChI=1S/C22H24N4O6S/c27-19(26-22-23-8-1-9-24-22)7-4-14-3-6-18(33-14)21(30)25-15(11-20(28)29)13-2-5-16-17(10-13)32-12-31-16/h2-3,5-6,10,15H,1,4,7-9,11-12H2,(H,25,30)(H,28,29)(H2,23,24,26,27)/t15-/m0/s1 | PDB
KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar AffyNet
| CHEMBL PC cid PC sid UniChem
Similars
| PubMed
| n/a | n/a | >1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Aventis Pharma Deutschland GmbH
Curated by ChEMBL
| Assay Description Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50% |
Bioorg Med Chem Lett 11: 2011-5 (2001)
BindingDB Entry DOI: 10.7270/Q2N87930 |
More data for this Ligand-Target Pair | |